At a glance
- Originator Eisai Co Ltd
- Class Vasodilators
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders; Heart failure; Pulmonary hypertension
Most Recent Events
- 11 Dec 1998 Preclinical development for Heart failure in Japan (Unknown route)
- 11 Dec 1998 Preclinical development for Pulmonary hypertension in Japan (Unknown route)
- 25 Sep 1998 Preclinical development for Cardiovascular disorders in Japan (Unknown route)